A Prospective Randomized, Open-label Phase 2 Study of Immune Checkpoint Inhibition, Nivolumab With or Without Ipilimumab in Combination With Radiation Therapy in Pretreated Patients With Metastatic Pancreatic Cancer.

Trial Profile

A Prospective Randomized, Open-label Phase 2 Study of Immune Checkpoint Inhibition, Nivolumab With or Without Ipilimumab in Combination With Radiation Therapy in Pretreated Patients With Metastatic Pancreatic Cancer.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Nivolumab (Primary) ; Ipilimumab
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms CheckPAC
  • Most Recent Events

    • 02 Dec 2016 Status changed from not yet recruiting to recruiting.
    • 10 Nov 2016 Planned End Date changed from 1 Aug 2019 to 1 Nov 2019.
    • 10 Nov 2016 Planned primary completion date changed from 1 Aug 2018 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top